Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Background/Aims: Serum fibrosis scores comprised of common laboratory tests have high utility to assess severity of liver fibrosis. We aimed to derive and validate a hepatocellular carcinoma (HCC) risk score based on serum fibrosis scores to predict HCC in treatment-naïve chronic hepatitis B (CHB) patients. Methods: Fifteen thousand one hundred eighty-seven treatment-naïve adult CHB patients were identified to form the training cohort in this retrospective study. Individual fibrosis score was included to construct a new HCC prediction score. The score was externally validated in an independent treatment-naïve Korean CHB cohort. Results: 180/15,187 patients (1.2%) in training cohort and 47/4,286 patients (1.1%) in validation cohort developed HCC during a mean follow-up of 52 and 50 months, respectively. The newly developed HCC risk score, Liang score, is composed of gender, age, hepatitis B virus DNA, fibrosis-4 (FIB-4) index, and ranges from 0 to 22. Area under the timedependent receiver operating characteristic curve of Liang score was 0.79 (95% confidence interval, 0.70–0.89). A cutoff value of nine provided an extremely high negative predictive value of 99.9% and high sensitivity of 90.0% at 5 years in the validation cohort. Patients with Liang score ≤9 had HCC incidence <0.2% per year in both training and validation cohorts, in whom HCC surveillance might be exempted. Conclusion: A novel HCC risk score, Liang score, based on FIB-4 index, is applicable and accurate to identify treatmentnaïve CHB patients with very low risk of HCC to be exempted from HCC surveillance.
Abstract
Background/Aims: Serum fibrosis scores comprised of common laboratory tests have high utility to assess severity of liver fibrosis. We aimed to derive and validate a hepatocellular carcinoma (HCC) risk score based on serum fibrosis scores to predict HCC in treatment-naïve chronic hepatitis B (CHB) patients. Methods: Fifteen thousand one hundred eighty-seven treatment-naïve adult CHB patients were identified to form the training cohort in this retrospective study. Individual fibrosis score was included to construct a new HCC prediction score. The score was externally validated in an independent treatment-naïve Korean CHB cohort. Results: 180/15,187 patients (1.2%) in training cohort and 47/4,286 patients (1.1%) in validation cohort developed HCC during a mean follow-up of 52 and 50 months, respectively. The newly developed HCC risk score, Liang score, is composed of gender, age, hepatitis B virus DNA, fibrosis-4 (FIB-4) index, and ranges from 0 to 22. Area under the timedependent receiver operating characteristic curve of Liang score was 0.79 (95% confidence interval, 0.70–0.89). A cutoff value of nine provided an extremely high negative predictive value of 99.9% and high sensitivity of 90.0% at 5 years in the validation cohort. Patients with Liang score ≤9 had HCC incidence <0.2% per year in both training and validation cohorts, in whom HCC surveillance might be exempted. Conclusion: A novel HCC risk score, Liang score, based on FIB-4 index, is applicable and accurate to identify treatmentnaïve CHB patients with very low risk of HCC to be exempted from HCC surveillance.
참고문헌 (35)
- Polaris Observatory Collaborators, "Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016 : a modelling study", Lancet Gastroenterol Hepatol, 3, pp.383~403 (2018)
- Singal AG, "Epidemiology and surveillance for hepatocellular carcinoma : new trends", J Hepatol, 72, pp.250~261 (2020)
- Wong GL, "Surveillance programme for hepatocellular carcinoma improves the survival of patients with chronic viral hepatitis", Liver Int, 28, pp.79~87 (2008)
- Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
- European Association for the Study of the Liver, "EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
- Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B : a 2015 update", Hepatol Int, 10, pp.1~98 (2016)
- Wong GL, "Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis", Hepatology, 58, pp.1537~1547 (2013)
- Yip TC, "Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China", Gastroenterology, 158, pp.215~225.e6 (2020)
- Bonacci M, "Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the grey zone", Aliment Pharmacol Ther, 47, pp.1397~1408 (2018)
- Sinn DH, "Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load", Hepatology, 62, pp.694~701 (2015)
- Wong VW, "Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers", J Clin Oncol, 28, pp.1660~1665 (2010)
- Wong GL, "Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B", J Hepatol, 60, pp.339~345 (2014)
- Wong VW, "Surrogate end points and long-term outcome in patients with chronic hepatitis B", Clin Gastroenterol Hepatol, 7, pp.1113~1120 (2009)
- Liang LY, "Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma", Aliment Pharmacol Ther, 49, pp.1509~1517 (2019)
- Cheng JYK, "Advances in the diagnosis and treatment of liver fibrosis", Hepatoma Res, 3, pp.156~169 (2017)
- Wong GL, "Development of a non-invasive algorithm with transient elastography(Fibroscan)and serum test formula for advanced liver fibrosis in chronic hepatitis B", Aliment Pharmacol Ther, 31, pp.1095~1103 (2010)
- Brouwer WP, "Prediction of long-term clinical outcome in a diverse chronic hepatitis B population : role of the PAGE-B score", J Viral Hepat, 24, pp.1023~1031 (2017)
- "Combating hepatitis B and C to reach elimination by 2030: advocacy brief"[URL]
- Cheng M, "Development journey of clinical data analysis and reporting system(CDARS)in hospital authority of Hong Kong", MEDINFO, 160, pp.1468~ (2010)
- Yip TC, "Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients", J Hepatol, 68, pp.63~72 (2018)
- Wong GL, "Chronic kidney disease progression in patients with chronic hepatitis B on tenofovir, entecavir, or no treatment", Aliment Pharmacol Ther, 48, pp.984~992 (2018)
- Yip TC, "On-treatment improvement of MELD score reduces death and hepatic events in patients with hepatitis B-related cirrhosis", Am J Gastroenterol, 113, pp.1629~1638 (2018)
- Lai JC, "Chronic hepatitis B increases liver-related mortality of patients with acute hepatitis E : a territorywide cohort study from 2000 to 2016", Clin Infect Dis, 67, pp.1278~1284 (2018)
- Wong JC, "Statins reduce the risk of liver decompensation and death in chronic viral hepatitis : a propensity score weighted landmark analysis", Aliment Pharmacol Ther, 46, pp.1001~1010 (2017)
- Vallet-Pichard A, "FIB-4 : an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest", Hepatology, 46, pp.32~36 (2007)
- Castéra L, "Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C", Gastroenterology, 128, pp.343~350 (2005)
- Heagerty PJ, "Time-dependent ROC curves for censored survival data and a diagnostic marker", Biometrics, 56, pp.337~344 (2000)
- Wong GL, "An aging population of chronic hepatitis B with increasing comorbidities : a territory-wide study from 2000 to 2017", Hepatology, 71, pp.444~455 (2020)
- Yotsuyanagi H, "Hepatitis B virus-related hepatocellular carcinoma in young adults : efficacy of nationwide selective vaccination", Hepatol Res, 50, pp.182~189 (2020)
- Yuen MF, "Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B", J Hepatol, 50, pp.80~88 (2009)
- Wong GL, "Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy", World J Gastroenterol, 19, pp.6515~6522 (2013)
- Marrero JA, "Diagnosis, staging, and management of hepatocellular carcinoma : 2018 practice guidance by the American Association for the Study of Liver Diseases", Hepatology, 68, pp.723~750 (2018)
- Ong TZ, "Ultrasonography is not reliable in diagnosing liver cirrhosis in clinical practice", Singapore Med J, 44, pp.293~295 (2003)
- Wong GL, "Meta-analysis : the association of hepatitis B virus genotypes and hepatocellular carcinoma", Aliment Pharmacol Ther, 37, pp.517~526 (2013)
- Chan HL, "Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma", Gut, 53, pp.1494~1498 (2004)